Lymphangiomyomatosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 10: | Line 10: | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category: Disease]] | [[Category: Disease]] | ||
[[Category: Hematology]] | [[Category: Hematology]] | ||
Latest revision as of 18:00, 24 August 2015
Template:Lymphangiomyomatosis Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
- Doxycycline has been proposed as a treatment with minimal side-effects.[1]
- Sirolimus is being tested for the treatment of LAM. The MILES Trial (Multicenter International LAM Efficacy of Sirolimus Trial) is now underway. The first site, the University of Cincinnati, is open for enrollment. The National Institutes of Health will open enrollment soon. The MILES Trial is randomized, double-blinded, and placebo-controlled. The objective of the Trial is to determine if sirolimus has a beneficial effect on lung function in LAM patients.
References
- ↑ Moses MA, Harper J, Folkman J (2006). "Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs". New Engl J Med. 354 (24): 2621&ndash, 22.